Kesimpta 20 mg solution for injection in pre-filled syringe
Sponsors
Antwerp University Hospital, Novartis Pharma AG, Kyverna Therapeutics Inc., Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Conditions
Multiple sclerosisPrimary or Secondary Progressive Multiple SclerosisProgressive Multiple SclerosisRelapsing forms of Multiple Sclerosis (RMS)
Phase 2
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placebo-controlled randomized clinical trial (MACSiMiSE-BRAIN)
Active, not recruitingCTIS2023-503190-38-00
Start: 2023-11-23Target: 120Updated: 2025-11-07
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
Not yet recruitingCTIS2024-511168-10-00
Target: 88Updated: 2024-10-07
PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial.
WithdrawnCTIS2025-520955-10-00
Target: 210Updated: 2025-10-20